Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Vedanta's Microbiome Therapy for IBD Disappoints

Vedanta Biosciences cuts 20% of workforce after VE202 failed to meet primary efficacy in Phase 2 ulcerative colitis trial, shifting focus to VE303 and VE707 therapies.

Summary by Pharmaphorum
Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce

5 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Wednesday, August 13, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
Search
BlindspotLocal